PHIO CIK: 1533040

Phio Pharmaceuticals Corp.

  • United States
  • Healthcare
  • Biotech
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25

Assets

(positive)
Change from FY21 to FY25
millions USD
FY21:
24.7
FY22:
12.4
FY23:
9.32
FY24:
5.74
FY25:
21.5
(positive)
Change from FY21 to FY25
millions USD
FY21:
0.44
FY22:
0.37
FY23:
0.04
FY24:
0.00
FY25:
0.01
Total assets
Change from FY21 to FY25
millions USD
FY21:
25.2
FY22:
12.8
FY23:
9.36
FY24:
5.74
FY25:
21.5

Liabilities & Equity

(negative)
Change from FY21 to FY25
millions USD
FY21:
3.07
FY22:
1.94
FY23:
1.63
FY24:
1.02
FY25:
1.34
(negative)
Change from FY21 to FY25
millions USD
FY21:
0.17
FY22:
0.04
FY23:
0
FY24:
0
FY25:
0
(positive)
Change from FY21 to FY25
millions USD
FY21:
21.9
FY22:
10.8
FY23:
7.73
FY24:
4.72
FY25:
20.1
Total liabilities & equity
Change from FY21 to FY25
millions USD
FY21:
25.2
FY22:
12.8
FY23:
9.36
FY24:
5.74
FY25:
21.5

All amounts in millions USD Data sources:SEC EDGARTwelve Data